Clinical Trials
16 trialsNCT04550442 2026-06-05
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04160052 2026-02-12
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT05209152 2025-07-14
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
Phase 1 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT03593915 2023-11-09
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03614728 2023-02-06
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
Phase 1/2 Terminated
NCT00234000 2020-07-31
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03146871 2019-04-18
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
University of Southern California
Phase 2 Terminated
NCT01957644 2019-02-08
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
Phase 1 Terminated
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT00997243 2017-05-10
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT02147873 2016-10-20
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
TetraLogic Pharmaceuticals
Phase 2 Terminated
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated